Testing ZM008 alone and with toripalimab for advanced cancers
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy, Kidney & urinary, Lungs & breathing, Skin clinical trials.
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be one of the specific types listed, such as lung, breast, head and neck, prostate, colorectal, pancreatic, bile duct, ovarian, lymphoma, kidney, or bladder cancer, and it must be advanced and not responding to standard treatments.
- You should have tumors that can be measured on scans like CT or MRI.
- Your overall health should be good enough that you are up and about at least half the day (ECOG 0-1).
- You must meet certain blood count and organ function requirements, like having enough red cells, white cells, and platelets, and healthy liver and kidneys.
- You cannot have active brain metastases, serious heart problems, uncontrolled infections, or a history of certain lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This study tests a new drug called LM-168, either alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that haven't responded to standard treatments. It aims to see if this combination is safe and effective, and may offer a new option when others have stopped working.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.